Empty Capsule Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Establishing an empty capsule manufacturing facility requires navigating a multi-agency regulatory architecture spanning CDSCO manufacturing licences, BIS quality standards, environmental compliance, and pharmaceutical GMP certification under Schedule M of the Drugs and Cosmetics Rules, 1945.

• CDSCO Manufacturing Licence under Form 25 (for allopathic capsules) and Form 26 (for Ayurvedic/Herb-based capsules) from the State Drugs Licensing Authority. Facility must comply with WHO-GMP certification requirements under Schedule M for pharmaceutical excipients classified as drug intermediates.
• BIS IS 1585:2018 certification for hard gelatin capsule specifications covering dimensional uniformity, moisture content limits (12.5-17.5% w/w for gelatin, 4-7% for HPMC), and dissolution parameters. Bureau of Indian Standards testing at accredited laboratories mandatory for each production batch.
• Pollution Control Board Consent to Establish and Consent to Operate under the Water (Prevention and Control of Pollution) Act, 1974 and Air (Prevention and Control of Pollution) Act, 1981. Effluent treatment plant mandatory for gelatin processing waste streams containing chromium and sulfates.
• Fire Safety NOC from the local Fire Department. Gelatin processing involves gelatinisation temperatures of 55-65 degrees Celsius with associated steam and hot water systems. HPMC capsule lines require lower temperature profiles but similar solvent handling protocols.
• Drug Manufacturing Licence under Schedule M certification requires qualified person appointment with minimum 2 years pharmaceutical manufacturing experience. Quality control laboratory accreditation under NABL (IS0/IEC 17025) mandatory for in-house testing of raw material and finished capsule specifications.
• GST Registration and composition scheme eligibility assessment. Empty capsules attract 12% GST under HSN 9602 for gelatin articles. Pharmaceutical-grade capsule inputs attract 5% GST under ITC claimed regime.
• Environmental Impact Assessment (EIA) Notification 2006 compliance if land acquisition exceeds 50 hectares or if located within 10 km of ecologically sensitive zones. For standalone manufacturing units in approved pharmaceutical SEZs or industrial areas, EIA exemption applies under delegated powers to State Pollution Control Boards.
• Employee provident fund (EPF) and Employee State Insurance (ESI) registration mandatory for workforce exceeding 10 and 20 employees respectively. Factory licence under the Factories Act, 1948 with annual renewal required for establishments employing more than 10 workers with power consumption exceeding statutory thresholds.

KAMRIT Financial Services LLP manages the complete regulatory filing architecture for this project, from CDSCO manufacturing licence applications to BIS testing coordination and Pollution Control Board consent management. Our in-house regulatory affairs team maintains active liaison with State Drugs Licensing Authorities in Gujarat, Himachal Pradesh, and Maharashtra pharmaceutical hubs, reducing approval timelines from industry-standard 18-24 months to 12-15 months for clients pursuing bankable DPR submissions.

The empty capsule market in India is differentiated from adjacent pharmaceutical excipient categories by its direct relationship with final dosage form manufacturing. While excipients broadly include binders, fillers, and disintegrants that are formulation-specific, empty capsules serve as a universal delivery platform across Ayurvedic, allopathic, and nutraceutical segments. The hard gelatin capsule segment commands approximately 68% market share by volume, with HPMC vegetarian capsules growing at 22% CAGR as vegan consumer preference strengthens and gelatin supply costs fluctuate with bovinehide commodity cycles.

The Ayurvedic and herbal formulation capsule sub-segment is expanding at 18% CAGR, driven by FSSAI's AYUSH division creating clearer regulatory pathways for traditional medicine encapsulation. Probiotic and live bacterial capsule delivery is the fastest-growing sub-segment at 26% CAGR, requiring specialized acid-resistant enteric capsule technology that commands 35% margin premium over standard formulation capsules. Clinical nutrition and sports nutrition capsule formats are growing at 19% CAGR, increasingly displacing tablet formats in premium product lines.

The veterinary pharmaceutical capsule market operates on distinct regulatory pathways under CDSCO's veterinarian division, with lower margin but steady demand from poultry and dairy sector growth.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

Empty capsule manufacturing technology choices critically determine the CapEx quantum and operating cost structure within the ₹4.5 crore to ₹80 crore investment band. The primary technology categories span fully automatic, semi-automatic, and manual capsule filling production lines, with equipment sourcing decisions spanning Indian, European, and Chinese manufacturers. For production capacities below 100 million capsules per month, Indian-manufactured automatic capsule machines from ACG's domestic production and Bosch Packaging offer attractive cost economics at ₹1.8 crore to ₹3.2 crore per line, with 30,000 to 45,000 capsules per hour throughput.

European equipment from IMA (Italy) and MG2 (Italy) commands 2.5-3x price premium but offers superior dimensional tolerances and faster changeover times for mixed product runs, critical for Ayurvedic capsule manufacturers requiring frequent format changes. Chinese equipment from Shanghai Pharmaceutical Machinery offers the lowest capital entry point at 40-50% of European equivalent pricing but carries higher maintenance overhead and quality consistency concerns that complicate CDSCO audit compliance. For hard gelatin capsule shell production, the dipping process requires gelatin dissolution systems with precise temperature control (55-65°C maintained within ±0.5°C), rotary die systems for capsule body and cap formation, and classification systems for size sorting (000, 00, 0, 1, 2, 3, 4).

HPMC capsule production requires specialized gellan gum and pullulan coating systems that increase raw material cost by 25-30% over gelatin equivalents. Energy consumption benchmarks range from 85-120 kWh per million capsules produced for fully automatic lines, with steam generation for gelatin processing representing 35-40% of total energy costs. Water consumption of 2.5-3.5 litres per million capsules mandates zero-liquid discharge wastewater treatment systems in water-stressed industrial locations.

For a empty capsule plant project at ₹4.5 crore - ₹80 crore CapEx with a 3.8 - 6.4-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

For empty capsule plant at ₹4.5 crore - ₹80 crore CapEx and 3.8 - 6.4-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For this category specifically, KAMRIT also models supplier concentration risk, currency exposure where input-imports exceed 25 percent of CapEx, and the working-capital cycle stretch in the first 18 months of commissioning. The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.